ALK positive
Showing 1 - 25 of >10,000
Iruplinalkib in Treatment of ALK-Positive Non-Small Cell Lung
Recruiting
- Non-small Cell Lung Cancer (NSCLC)
-
Jinan, Shandong, ChinaShandong Cancer Hospital and Institute
Aug 8, 2023
ALK Positive NSCLC Trial in Guangzhou (Loratinib)
Recruiting
- ALK Positive Non-small Cell Lung Cancer
-
Guangzhou, Guangdong, ChinaGuangdong Provincial Perople's Hospital
Oct 19, 2023
NSCLC(NSCLC) Trial in Jinan (WX-0593 Tablets)
Not yet recruiting
- Non-Small Cell Lung Cancer(NSCLC)
- WX-0593 Tablets
-
Jinan, Shandong, ChinaShandong Cancer Hospital and Institute
Mar 1, 2023
ALK-positive NSCLC Trial in Shanghai (Alkotinib Capsules)
Recruiting
- ALK-positive Non-small Cell Lung Cancer
- Alkotinib Capsules
-
Shanghai, Shanghai, ChinaShanghai Pulmonary Hospital
Nov 28, 2022
Non-small-cell Lung Carcinoma Trial in Beijing (SY-3505)
Recruiting
- Non-small-cell Lung Carcinoma
-
Beijing, ChinaCancer Hospital, Chinese Academy of Medical Sciences
May 11, 2023
NSCLC Trial in Shanghai (WX-0593)
Active, not recruiting
- Non-small Cell Lung Cancer
-
Shanghai, ChinaShanghai Jiao Tong University Chest Hospital
Mar 24, 2023
ALK-positive NSCLC Trial in Jilin (XZP-3621)
Not yet recruiting
- ALK-positive NSCLC
-
Jilin, Chang Chun, ChinaJilin Province Cancer Hospital
Jul 29, 2022
ALK-positive NSCLC in Sweden: Sequencing of ALK Tyrosine Kinase
Completed
- ALK-positive NSCLC
- crizotinib
- +4 more
-
Sollentuna, SwedenPfizer Innovations AB
Mar 14, 2022
A Real World Study of Ensartinib in Advanced ALK-positive NSCLC
Recruiting
- Carcinoma, Non-Small-Cell Lung
- +2 more
-
Beijing, Beijing, ChinaDepartment of Respiratory and Critical Care Medicine, Peking Uni
Aug 10, 2022
ALK-positive NSCLC Trial in Dallas (Ceritinib, Stereotactic ablative body radiation)
Terminated
- ALK-positive Non-small Cell Lung Cancer
- Ceritinib
- Stereotactic ablative body radiation
-
Dallas, TexasUT Southwestern Medical Center
Jan 31, 2023
Anaplastic Lymphoma Kinase-Positive Non-small Cell Lung Cancer
Active, not recruiting
- Non-Small-Cell Lung Carcinoma
-
New York, New YorkPfizer Inc
Apr 12, 2022
Advanced NSCLC Trial in India (Lorlatinib)
Completed
- Advanced Non-Small Cell Lung Cancer
-
New Delhi, Delhi, India
- +11 more
Sep 13, 2022
NSCLC Trial in Tianjin (Ensartinib, Placebo)
Recruiting
- Non-small Cell Lung Cancer
- Ensartinib
- Placebo
-
Tianjin, ChinaTianJin Medical University Cancer Institute & Hospital
Jul 13, 2022
Non Small Cell Lung Cancer Trial in Goyang-si (Brigatinib)
Recruiting
- Non Small Cell Lung Cancer
-
Goyang-si, Gyeonggi-do, Korea, Republic ofNational Cancer Center
Apr 4, 2022
Non Small Cell Lung Cancer Trial (TGRX-326, Crizotinib)
Not yet recruiting
- Non Small Cell Lung Cancer
- (no location specified)
Oct 8, 2023
Ensatinib in alK-positive Patients Undergoing Initial Treatment
Recruiting
- ALK Positive
- +2 more
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
Nov 16, 2021
Circular RNAs in ALKpositive Anaplastic Large-cell Lymphoma
Active, not recruiting
- ALK-Positive Anaplastic Large Cell Lymphoma
- RNAseq
-
Toulouse, FranceIUCT-Oncopole University Hospital
Jul 3, 2023
NSCLC Trial in Beijing (SY-3505)
Recruiting
- Non-small Cell Lung Cancer
-
Beijing, Beijing, ChinaCancer Hospital, Chinese Academy of Medical Sciences
Mar 17, 2022
Anaplastic Large Cell Lymphoma, ALK-Positive, Inflammatory Myofibroblastic Tumor, Other Solid Tumor Trial in Utrecht
Recruiting
- Anaplastic Large Cell Lymphoma, ALK-Positive
- +2 more
-
Paris, France
- +1 more
Sep 27, 2022
NSCLC Stage IV, ALK Fusion Protein Expression Trial (Peptide vaccine)
Not yet recruiting
- NSCLC Stage IV
- ALK Fusion Protein Expression
- Peptide vaccine
- (no location specified)
Jul 21, 2023
NSCLC Trial in Shijiazhuang (Ensartinib)
Not yet recruiting
- Non-small Cell Lung Cancer
-
Shijiazhuang, Hebei, ChinaJun Feng Liu
Feb 6, 2022
ALK Fusion Protein Expression, Adjuvant Therapy, NSCLC Trial (Ensatinib, chemo)
Not yet recruiting
- ALK Fusion Protein Expression
- +2 more
- (no location specified)
Jan 10, 2022